SevenBridge Financial Group LLC Purchases 993 Shares of Zoetis Inc. (NYSE:ZTS)

SevenBridge Financial Group LLC raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 44.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,237 shares of the company’s stock after purchasing an additional 993 shares during the quarter. SevenBridge Financial Group LLC’s holdings in Zoetis were worth $564,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Callahan Advisors LLC raised its holdings in shares of Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after acquiring an additional 6,221 shares during the last quarter. CIBC Asset Management Inc raised its stake in shares of Zoetis by 24.1% in the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after purchasing an additional 46,050 shares during the last quarter. Pensionfund Sabic raised its stake in shares of Zoetis by 55.6% in the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after purchasing an additional 4,000 shares during the last quarter. PFW Advisors LLC purchased a new position in Zoetis during the 4th quarter worth $1,764,000. Finally, Alberta Investment Management Corp boosted its holdings in Zoetis by 2,050.0% during the fourth quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock worth $4,904,000 after purchasing an additional 28,700 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 1.7 %

ZTS opened at $161.77 on Wednesday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The stock’s 50 day moving average price is $166.26 and its 200-day moving average price is $174.05. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.33. The stock has a market cap of $72.44 billion, a price-to-earnings ratio of 29.57, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. On average, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.24%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is currently 36.56%.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have commented on the stock. Stifel Nicolaus lowered their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Barclays lifted their target price on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Piper Sandler increased their price objective on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Morgan Stanley decreased their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Finally, StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.